XVIPF (Xvivo Perfusion AB) GF Value Rank: 8 (As of Jun. 26, 2026) — 100% Above Median


XVIPF Xvivo Perfusion AB XVIPF
91 GF Score
Price $29.00
GF Value $42.07
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is Xvivo Perfusion AB GF Value Rank?

Xvivo Perfusion AB XVIPF -1.32% 91 GF Value Rank is 8 as of Jun. 26, 2026, which is 100% above its 10-year median of 4.00. GuruFocus rates XVIPF with a GF Score™ of 91/100 and a GF Value™ of $42.07 (Significantly Undervalued). The stock has 2 warning signs investors should review.

Xvivo Perfusion AB has the GF Value Rank of 8.

GF Value Rank evaluates the exclusive GuruFocus valuation and performance of a stock, rated on a scale from 1 to 10. It is determined by the price-to-GF-Value (P/GF Value) ratio, a proprietary metric calculated based on historical multiples along with an adjustment factor based on a company's past returns and growth and future estimates of the business' performance.

GuruFocus found that for valuation, we cannot simply give stocks a better GF Value rank simply because they have a lower P/GF Value ratio. Backtesting shows that over the long term, the two worst-performing groups are the most expensive group (with the highest P/GF Value ratio) and the least expensive group (with the lowest P/GF Value ratio).

We can understand why the most expensive group underperforms. We were initially puzzled by the underperformance of the least expensive group, but we realized there is a reason why some stocks are super cheap. If they look too undervalued, it is often because the businesses behind them are poor quality. The market realized this and gave them low valuations. In a way, the market is efficient.

After multiple backtesting analyses, we granted the stocks in third-cheapest percentile the highest GF Value rank, as they have performed the best over a full market cycle. Stock performance is actually not as sensitive to valuation as it is to growth and profitability. On average, the companies in the 20%-50% valuation groups have similar performances. Therefore, we should avoid the most expensive and the least expensive stocks. We can be more tolerant of valuation.

A higher score indicates a stock with a relatively low valuation and substantial potential for outperformance. Conversely, a lower score often reflects stocks that are either highly overvalued or deeply undervalued, both of which tend to underperform.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Xvivo Perfusion AB GF Value Rank Related Terms

XVIPF vs ABT, SYK, MDT: GF Value Rank Comparison

For the Medical Devices subindustry, Xvivo Perfusion AB's GF Value Rank, along with its competitors' market caps and GF Value Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Xvivo Perfusion AB GF Value Rank vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Xvivo Perfusion AB's GF Value Rank distribution charts can be found below:

* The bar in red indicates where Xvivo Perfusion AB's GF Value Rank falls into.


XVIPF
91GF Score
Xvivo Perfusion AB XVIPF
GF Value Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about GF Value Rank →
What does a GF Value Rank of 8 mean?
Xvivo Perfusion AB (XVIPF) has a GF Value Rank of 8 as of Jun. 26, 2026. GF Value Rank is given based on historical multiples along with past returns, growth and future estimates of the business' performance. View historical data on Xvivo Perfusion AB and its competitors. This is 100% above median its historical median of 4.00. Over the past decade, Xvivo Perfusion AB's GF Value Rank has ranged from 1.00 to 10.00.
Is Xvivo Perfusion AB's GF Value Rank too high?
Xvivo Perfusion AB's current GF Value Rank of 8 is 100% above median its 10-year median of 4.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 10.00. Overall, Xvivo Perfusion AB has a GF Score™ of 91/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Xvivo Perfusion AB's GF Value Rank compare to ABT and SYK?
Xvivo Perfusion AB's GF Value Rank of 8 can be compared against companies in the Medical Devices & Instruments industry. Historically, Xvivo Perfusion AB's own GF Value Rank has ranged from 1.00 to 10.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Value Rank for a Medical Devices & Instruments company?
A good GF Value Rank depends on the Medical Devices & Instruments industry context. However, GF Value Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Value Rank mean?
A high GF Value Rank can signal that a stock is expensive relative to its fundamentals. GF Value Rank is given based on historical multiples along with past returns, growth and future estimates of the business' performance. View historical data on Xvivo Perfusion AB and its competitors. Xvivo Perfusion AB's current GF Value Rank is 8, which is 100% above median its own 10-year median of 4.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xvivo Perfusion AB stock overvalued right now?
Based on GuruFocus' analysis, Xvivo Perfusion AB (XVIPF) is currently considered Significantly Undervalued. The stock's GF Value™ is $42.07, compared to a current price of $29.00 — trading 31.1% below its estimated fair value. The current GF Value Rank is 8, which is 100% above median its 10-year median of 4.00. Xvivo Perfusion AB's overall GF Score™ is 91/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Value Rank calculated?
GF Value Rank is calculated from a company's financial statements. For Xvivo Perfusion AB (XVIPF), the current GF Value Rank is 8 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Xvivo Perfusion AB (XVIPF) Overvalued in 2026?

Based on GuruFocus' analysis, Xvivo Perfusion AB stock appears to be undervalued. The current stock price of $29.00 is trading 31.1% below its estimated GF Value™ of $42.07. GuruFocus considers Xvivo Perfusion AB to be Significantly Undervalued.

Key valuation signals for XVIPF:

  • GF Value Rank: 8 (100% above median its 10-year median of 4.00)
  • GF Value™: $42.07 vs. price of $29.00 (31.1% below fair value)
  • GF Score™: 91/100 with 2 warning signs

No single metric tells the full story. See the XVIPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Xvivo Perfusion AB Business Description

Address Gemenskapens gata 9, Molndal, SWE, SE-431 53
Xvivo Perfusion AB is a medical technology company dedicated to extending the life of organs so transplant teams around the world can save more lives. Its solutions allow clinicians and researchers to push the boundaries of transplantation medicine. It operates in three segments, namely Thoracic: sales of lung and heart transplant products; Abdominal: sales of liver and kidney transplant products and perfusion services; and Services: revenue from the sale of services related to organ recovery, as well as digital products for communication and workflow management at transplantation clinics. The majority of revenue is derived from the Thoracic segment, and geographically, the majority is from the United States.
91GF Score

Get the complete analysis for XVIPF

GF Value Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$29.00
Price
$42.07
GF Value